This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual American Society of Hematology (ASH) 2021 conference.
Download your copy now for the data-driven news, comment and analysis..
Agios and Forma take different paths in sickle cell disease
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
Bluebird looks to revive Lentiglobin
Data in sickle cell disease look encouraging,
but a filing is a way away.
Data in sickle cell disease look encouraging,
but a filing is a way away.
Precision moves quickly to deal with allo disappointment
Like its two competitors,
Precision shows a lack of
durability with its allogeneic
Car-T approach but makes
a quick move to next-gen assets.
Like its two competitors,
Precision shows a lack of
durability with its allogeneic
Car-T approach but makes
a quick move to next-gen assets.
Global Blood stems the bleeding
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Another factor fade, courtesy of Pfizer and Sangamo
Pfizer and Sangamo’s haemophilia A gene therapy candidate giroctocogene fitelparvovec was supposed to be more durable than Biomarin’s rival project valrox, but this now looks in doubt.
Pfizer and Sangamo’s haemophilia A gene therapy candidate giroctocogene fitelparvovec was supposed to be more durable than Biomarin’s rival project valrox, but this now looks in doubt.
Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Bristol reveals its sons of Revlimid
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
The sun sets on Kymriah, but Novartis has a plan
Novartis unveils the first clinical
backing for a two-day
manufacturing technique
that it hopes will recharge its Car-T efforts.
Novartis unveils the first clinical
backing for a two-day
manufacturing technique
that it hopes will recharge its Car-T efforts.
